---
title: "Sumitomo Pharma Profit Jumps on U.S. Asset Transfer and Asian Stake Sale"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286196456.md"
description: "Sumitomo Pharma Co., Ltd. reported significant year-on-year gains for the fiscal year ending March 31, 2026, with net sales rising 82.9% to ¥249.5 billion and ordinary income increasing over fourfold. This growth is attributed to the acquisition of U.S. assets and a partial stake sale in an Asian business. Despite these gains, the overall impact on Sumitomo Chemical's consolidated earnings forecast is deemed immaterial. The current analyst rating for Sumitomo Chemical Co. (JP:4005) is a Hold with a price target of Yen520.00."
datetime: "2026-05-13T04:31:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286196456.md)
  - [en](https://longbridge.com/en/news/286196456.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286196456.md)
---

# Sumitomo Pharma Profit Jumps on U.S. Asset Transfer and Asian Stake Sale

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Sumitomo Chemical Co ( (JP:4005) ) has issued an update.

Sumitomo Chemical reported that its consolidated subsidiary Sumitomo Pharma Co., Ltd. posted sharp year-on-year gains in non-consolidated results for the fiscal year ended March 31, 2026, driven by an 82.9% rise in net sales to ¥249.5 billion and a more than fourfold increase in ordinary income. Despite these sizable movements at the subsidiary level, the parent said the overall impact on its consolidated earnings forecast remains immaterial.

The surge in Sumitomo Pharma’s performance reflects the August 2025 acquisition of substantially all U.S. assets, including patent rights, for three key products from group entities Sumitomo Pharma Switzerland GmbH and Urovant Sciences GmbH, allowing the company to book their sales directly. Ordinary income was further buoyed by dividend income from the Swiss subsidiary, while net income benefited from gains on sales of shares in affiliates following the partial transfer of an Asian business stake, underscoring an internal reallocation of assets and earnings streams within the Sumitomo group.

The most recent analyst rating on (JP:4005) stock is a Hold with a Yen520.00 price target. To see the full list of analyst forecasts on Sumitomo Chemical Co stock, see the JP:4005 Stock Forecast page.

**More about Sumitomo Chemical Co**

Sumitomo Chemical Co. is a diversified Japanese chemical manufacturer with operations spanning petrochemicals, energy and functional materials, IT-related chemicals, health and crop sciences, and pharmaceuticals. Through its consolidated subsidiary Sumitomo Pharma Co., Ltd., the group is active in the prescription drug market, with a particular focus on key products in the United States and growth opportunities in Asian pharmaceutical businesses.

**Average Trading Volume:** 14,407,771

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** Yen832B

For an in-depth examination of 4005 stock, go to TipRanks’ Overview page.

### Related Stocks

- [4005.JP](https://longbridge.com/en/quote/4005.JP.md)
- [4506.JP](https://longbridge.com/en/quote/4506.JP.md)

## Related News & Research

- [J.P. Morgan Keeps Their Buy Rating on Sumitomo (SSUMF)](https://longbridge.com/en/news/273005857.md)
- [Sumitomo Osaka Cement (TSE:5232) Net Margin Improvement To 5% Challenges Bearish Narratives](https://longbridge.com/en/news/286546206.md)
- [Sumitomo Warehouse Overhauls Board and Executive Lineup to Bolster Global Logistics Focus](https://longbridge.com/en/news/286036945.md)
- [Sumiken Mitsui RoadLtd (TSE:1776) Margin Improvement Challenges Bearish Earnings Narratives](https://longbridge.com/en/news/286276765.md)
- [BUZZ-India's Zydus Lifesciences hits six-month peak on buyback plan](https://longbridge.com/en/news/286366278.md)